← Scroll for more →
Financial Statements — HMH
Balance Sheet
(in billions USD)| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 |
|---|---|---|---|---|
| Cash & Equivalents | 0.12 | -- | 0.10 | -- |
| Accounts Receivable | -- | 0.00 | -- | -- |
| Inventory | 0.25 | -- | 0.25 | -- |
| Total Current Assets | 0.65 | -- | 0.63 | -- |
| Property, Plant & Equipment | 0.20 | -- | 0.20 | -- |
| Goodwill | 0.31 | -- | 0.31 | -- |
| Total Non-current Assets* | 0.71 | -- | 0.73 | -- |
| Total Assets | 1.36 | 0.00 | 1.36 | -- |
| Total Current Liabilities | 0.22 | -- | 0.22 | -- |
| Long-term Debt | 0.20 | -- | 0.34 | 0.34 |
| Total Non-current Liabilities* | 0.30 | -- | 0.43 | -- |
| Total Liabilities | 0.52 | -- | 0.66 | -- |
| Retained Earnings | 0.03 | -- | -- | -- |
| Total Stockholder Equity | 0.21 | -- | 0.70 | -- |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2026 | Q1 2026 | Q2 2025 |
|---|---|---|---|
| Total Revenue | 170.82 | -- | 203.46 |
| Cost of Revenue | 109.52 | -- | 151.54 |
| Gross Profit | 61.30 | -- | 51.91 |
| Research & Development | 0.77 | -- | 0.65 |
| Selling, General & Admin | 60.35 | -- | 29.44 |
| Total Operating Expenses | 66.13 | -- | 31.16 |
| Operating Income | (4.83) | -- | 20.75 |
| Pretax Income | (9.52) | -- | 14.93 |
| Tax Provision | (4.51) | -- | 5.16 |
| Net Income | 4.98 | -- | 8.95 |
| Basic EPS | 0.43 | 17,240.00 | 0.13 |
| Diluted EPS | 0.42 | 17,240.00 | 0.13 |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q2 2026 |
|---|---|
| Operating Cash Flow | 25.16 |
| Capital Expenditures | 2.09 |
| Free Cash Flow* | 23.07 |
| Investing Cash Flow | (8.75) |
| Financing Cash Flow | 6.65 |
← Scroll for more columns →
* Derived from reported values